Das Economic Development Board of Singapore gab heute bekannt, dass Novartis einen neuen pharmazeutischen Produktionsstandort in Singapur eröffnen wird. Das neue Produktionswerk soll neben anderen pharmazeutischen Marken von Novartis auch Tabletten herstellen. Ziel der Expansion ist es, dem Unternehmenswachstum sowie neuen Produktentwicklungen in Japan und den USA Unterstützung zu leisten. Die neue Produktionsfabrik in Singapur soll 2009 komplett in Betrieb gehen. Zusätzlich will Novartis bis 2012 ein großangelegtes Biotechologiezentrum in Singapur eröffnen, da biologische Präparate mittlerweile 25% des Novartisumsatzes darstellen. Novartis tätigt mit beiden Projekten in Singapur eine Gesamtinvestition von 700 Millionen USD, was die bisher größte Investition von Novartis in seine Produktionskapazitäten darstellt.
Singapur wird als Zentrum für Biotechnologie durch Novartis' Entscheidung weiter gestärkt. Novartis ist neben Lonza Biologics Singapore, GSK Biologics, Genentech und Lonza Biologics Tuas das fünfte pharmazeutische Großunternehmen, welches den Biotechnologiebereich nach Singapur auslagert.
-----------------------------------------------------------------------------------
Novartis opens new pharmaceutical plant and intends to build biotech facility in Singapore
· New pharmaceutical production plant to meet increasing demand for product supply in the US and Japan
· Novartis also expects to invest USD 700 million to build large-scale biotechnology facility in Singapore to support the company's growing pipeline of biopharmaceuticals
Singapore, October 29, 2007 - The Singapore Economic Development Board anoounced today that Novartis officially inaugurated a new state-of-the-art pharmaceutical manufacturing site in Tuas, Singapore, adding capacity to its global production network to meet business growth and support new product launches in the US and Japanese markets. The opening ceremony in Singapore was attended by Lim Hng Kiang, Minister of Trade and Industry for Singapore, and other officials, as well as Novartis senior executives.
The plant will manufacture solid dosage forms (tablets) of existing Novartis pharmaceutical brands, such as Diovan(R), and new products, like Tekturna(R). It is expected to be fully operational in 2009 and to employ around 160 employees.
In addition, Novartis unveiled its plan to build a large-scale biotechnology plant in Singapore to support the rapid growth of its biologics sector, which now accounts for 25 percent of the Novartis product pipeline. Novartis expects to invest approximately USD 700 million - its largest investment to date in manufacturing capacity - in the new, state-of-the-art cell-culture facility.
The biotech plant will employ more than 300 people when fully operational. Construction is expected to start in early 2008. Subject to regulatory approvals, the plant will be operational by the end of 2012.
"I am delighted to celebrate the opening of Novartis' new tabletting manufacturing facility as well its decision to locate one of its largest biologics manufacturing facility here in Singapore," said Minister for Trade and Industry, Mr Lim Hng Khiang. "The tabletting facility is a significant endorsement of Singapore as a value-adding partner to world-class pharmaceutical companies. The biologics facility further reinforces Singapore's position as a leading location for world-class biopharmaceuticals manufacturing. Within two years, we have attracted five biologics manufacturing investments."
The cell-culture plant will support both clinical and commercial production of potential new products in the area of biopharmaceutical therapies, primarily monoclonal antibodies, for indications such as rheumatoid arthritis, oncology, asthma and spinal chord injury.
The Novartis Institute for Tropical Diseases (NITD), Novartis Asia-Pacific Head Offices and a production facility for Ciba Vision are already based in Singapore. The new production facilities in Singapore will further strengthen Novartis as a global healthcare company, with a key presence in all major markets.
Media Contact:
Sheo S. Rai
Communications
Singapore Economic Development Board
Biomedical Sciences Group
sheo_shanker_rai@edb.gov.sg
Lale Karahan
Hotwire
Friedensstr. 6-10
60311 Frankfurt am Main
D: +49 (0) 69-25 66 93-85
F: +49 (0) 69-25 66 93-93
T: +49 (0) 69-25 66 93-0
E: lale.karahan@hotwirepr.com
Postadresse:
Weissfrauenstr. 12-16
60311 Frankfurt
Hotwire - Europe's fastest growing technology PR consultancy
Best Consultancy to Work For, Holmes Report, 2006
Top Com Trophée, Consumer Category, PR, 2006
European Tech Agency of the Year, Sabre Awards, 2005
Hotwire Public Relations Germany GmbH
Handelsregister B des Amtsgerichts Frankfurt HRB 53781
Geschäftsführer: John Laurence Anthony Ashley Wilson
Singapur wird als Zentrum für Biotechnologie durch Novartis' Entscheidung weiter gestärkt. Novartis ist neben Lonza Biologics Singapore, GSK Biologics, Genentech und Lonza Biologics Tuas das fünfte pharmazeutische Großunternehmen, welches den Biotechnologiebereich nach Singapur auslagert.
-----------------------------------------------------------------------------------
Novartis opens new pharmaceutical plant and intends to build biotech facility in Singapore
· New pharmaceutical production plant to meet increasing demand for product supply in the US and Japan
· Novartis also expects to invest USD 700 million to build large-scale biotechnology facility in Singapore to support the company's growing pipeline of biopharmaceuticals
Singapore, October 29, 2007 - The Singapore Economic Development Board anoounced today that Novartis officially inaugurated a new state-of-the-art pharmaceutical manufacturing site in Tuas, Singapore, adding capacity to its global production network to meet business growth and support new product launches in the US and Japanese markets. The opening ceremony in Singapore was attended by Lim Hng Kiang, Minister of Trade and Industry for Singapore, and other officials, as well as Novartis senior executives.
The plant will manufacture solid dosage forms (tablets) of existing Novartis pharmaceutical brands, such as Diovan(R), and new products, like Tekturna(R). It is expected to be fully operational in 2009 and to employ around 160 employees.
In addition, Novartis unveiled its plan to build a large-scale biotechnology plant in Singapore to support the rapid growth of its biologics sector, which now accounts for 25 percent of the Novartis product pipeline. Novartis expects to invest approximately USD 700 million - its largest investment to date in manufacturing capacity - in the new, state-of-the-art cell-culture facility.
The biotech plant will employ more than 300 people when fully operational. Construction is expected to start in early 2008. Subject to regulatory approvals, the plant will be operational by the end of 2012.
"I am delighted to celebrate the opening of Novartis' new tabletting manufacturing facility as well its decision to locate one of its largest biologics manufacturing facility here in Singapore," said Minister for Trade and Industry, Mr Lim Hng Khiang. "The tabletting facility is a significant endorsement of Singapore as a value-adding partner to world-class pharmaceutical companies. The biologics facility further reinforces Singapore's position as a leading location for world-class biopharmaceuticals manufacturing. Within two years, we have attracted five biologics manufacturing investments."
The cell-culture plant will support both clinical and commercial production of potential new products in the area of biopharmaceutical therapies, primarily monoclonal antibodies, for indications such as rheumatoid arthritis, oncology, asthma and spinal chord injury.
The Novartis Institute for Tropical Diseases (NITD), Novartis Asia-Pacific Head Offices and a production facility for Ciba Vision are already based in Singapore. The new production facilities in Singapore will further strengthen Novartis as a global healthcare company, with a key presence in all major markets.
Media Contact:
Sheo S. Rai
Communications
Singapore Economic Development Board
Biomedical Sciences Group
sheo_shanker_rai@edb.gov.sg
Lale Karahan
Hotwire
Friedensstr. 6-10
60311 Frankfurt am Main
D: +49 (0) 69-25 66 93-85
F: +49 (0) 69-25 66 93-93
T: +49 (0) 69-25 66 93-0
E: lale.karahan@hotwirepr.com
Postadresse:
Weissfrauenstr. 12-16
60311 Frankfurt
Hotwire - Europe's fastest growing technology PR consultancy
Best Consultancy to Work For, Holmes Report, 2006
Top Com Trophée, Consumer Category, PR, 2006
European Tech Agency of the Year, Sabre Awards, 2005
Hotwire Public Relations Germany GmbH
Handelsregister B des Amtsgerichts Frankfurt HRB 53781
Geschäftsführer: John Laurence Anthony Ashley Wilson
